Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study

Iptacopan (LNP023) is a novel, oral selective inhibitor of complement factor B under clinical development for paroxysmal nocturnal hemoglobinuria (PNH). In this ongoing open-label phase 2 study, PNH patients with active hemolysis were randomized to receive single-agent iptacopan twice daily at a dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Jun Ho, Wong, Lily, Ko, Bor-Sheng, Yoon, Sung-Soo, Li, Katie, Baltcheva, Irina, Nidamarthy, Prasanna Kumar, Chawla, Raghav, Junge, Guido, Yap, Eng Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636331/
https://www.ncbi.nlm.nih.gov/pubmed/35561315
http://dx.doi.org/10.1182/bloodadvances.2022006960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636331/
https://www.ncbi.nlm.nih.gov/pubmed/35561315
http://dx.doi.org/10.1182/bloodadvances.2022006960

Ejemplares similares